ew homeopathic medicine for prevention of COVID-19 infectio

Phase 2

Completed

• Registration Number: CTRI/2021/11/038253
• Lead Sponsor: Heritage Institute of Technology Kolkata

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-06-14
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

1. Age between 18 and 65 years

2. No major untreated diseases with apparently healthy status

3. No abnormality detected during clinical examination by experts and routine laboratory examinations (complete hemogram, fasting blood sugar, lipid profile, liver enzymes, urine for routine examination and microscopy, electrocardiogram, chest X-ray, ultrasonography of whole abdomen)

4. Literate patients; ability to read patient information sheet and voluntarily providing with written informed consent

Exclusion Criteria

1. Vulnerable population ââ?¬â?? unconscious, ambulatory, too sick for consultation, differently abled, terminally or critically ill patients, mentally incompetent subjects

2. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting quality of life or any organ failure

3. Pregnant and puerperal women, lactating mothers

4. Tobacco chewing and/or smoking, alcoholism, and/or any other form(s) of substance abuse and/or dependence

5. Self-reported immune-compromised state (e.g., HIV)

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Interferon alpha, beta and gammaTimepoint: At baseline, after 48 and 72 hours, and after 7 days. The sequence will be repeated thrice after an intervening wash-out period of 7 days

Secondary Outcome Measures

Name	Time	Method
Interleukin 1�², 6, 8, 10Timepoint: At baseline, after 48 and 72 hours, and after 7 days. The sequence will be repeated thrice after an intervening wash-out period of 7 days;Tumor growth factor �²1, �²3Timepoint: At baseline, after 48 and 72 hours, and after 7 days. The sequence will be repeated thrice after an intervening wash-out period of 7 days